Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humanwell Healthcare (Group) Co Buyback Yield % Chart
SHSE:600079 vs ZTS, UTHR: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Humanwell Healthcare (Group) Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Humanwell Healthcare (Group) Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Humanwell Healthcare (Group) Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Humanwell Healthcare (Group) Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humanwell Healthcare (Group) Co (SHSE:600079) has a Buyback Yield % of 0.00 as of Jul. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Humanwell Healthcare (Group) Co and its competitors. According to the industry distribution chart, Humanwell Healthcare (Group) Co ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Humanwell Healthcare (Group) Co's Buyback Yield % too high?
Humanwell Healthcare (Group) Co's current Buyback Yield % is 0.00. Based on the distribution chart, Humanwell Healthcare (Group) Co ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Humanwell Healthcare (Group) Co has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Humanwell Healthcare (Group) Co's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Humanwell Healthcare (Group) Co ranks #999999 out of 290 companies for Buyback Yield %. This places Humanwell Healthcare (Group) Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Humanwell Healthcare (Group) Co and its competitors. Humanwell Healthcare (Group) Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humanwell Healthcare (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co (SHSE:600079) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥21.64, compared to a current price of ¥17.59 — trading 18.7% below its estimated fair value. The current Buyback Yield % is 0.00. Humanwell Healthcare (Group) Co's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Humanwell Healthcare (Group) Co (SHSE:600079), the current Buyback Yield % is 0.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Humanwell Healthcare (Group) Co (SHSE:600079) Overvalued in 2026?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co stock appears to be undervalued.
The current stock price of ¥17.59 is trading 18.7% below its estimated GF Value™ of ¥21.64.
GuruFocus considers Humanwell Healthcare (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600079:
Buyback Yield %: 0.00
GF Value™: ¥21.64 vs. price of ¥17.59 (18.7% below fair value)
No single metric tells the full story. See the SHSE:600079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Humanwell Healthcare (Group) Co Business Description
Humanwell Healthcare (Group) Co Ltd is a China-based integrated healthcare solution provider. It provides medicinal products including fertility-regulating drugs, Uyghur medicine, traditional Chinese medicine, medical devices, over-the-counter medicines, anti-infection drugs, herbal medicines, and biological products. The organization has a business presence in China and other international countries.
58GF Score
Get the complete analysis for SHSE:600079
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600079 has been successfully added to your 
